FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Biomarkers associated with pulmonary exacerbations in a randomized trial of nintedanib for radiation pneumonitis. PMID 38740091 · Radiother Oncol · 2024-Jul The record describes a randomized trial with a drug intervention (nintedanib) for radiation pneumonitis in lung cancer patients, but the phase is not explicitly stated as Phase III or definitive. The primary outcome is biomarker analysis of serum proteins correlated with pulmonary exacerbations, which is not a time-to-event efficacy endpoint. Therefore, it does not meet the eligibility criteria for a primary/key secondary time-to-event outcome in a Phase III/IIIb or definitive trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. PMID 38704093 · Ann Oncol · 2024-Jul The record is a pre-planned translational analysis of a randomized trial (MITO END-3) in advanced endometrial cancer, reporting PFS by molecular subgroups. While it meets criteria for oncology, human, randomized, drug intervention, time-to-event endpoint, and original result, the phase of the parent trial is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata. Furthermore, the report type is a pre-planned translational/biomarker subgroup analysis, not the primary efficacy report of the randomized trial. Therefore, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Feasibility of intraoperative pathologic examination for sentinel lymph nodes during sentinel node navigation surgery in early gastric cancer: results of pathologic protocol for SENORITA trial. PMID 38647977 · Gastric Cancer · 2024-Jul The report is an oncology, human, randomized trial with an original result, but it is not eligible because it is not a Phase III/IIIb or Phase II/III trial, lacks a drug-containing intervention, and does not report a primary or key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study). PMID 38493275 · Bone Marrow Transplant · 2024-Jul The record describes an observational study (ATOS) that references a prior Phase III randomised trial (RCT) for comparison. While it reports time-to-event efficacy endpoints for patients with haematological malignancies, the study itself is not the original report of a randomised trial with a drug intervention. The drug ATLG is used for GvHD prophylaxis in the context of unrelated donor transplantation, not as a primary cancer therapeutic drug intervention in a definitive randomised trial. The original RCT is not provided here. Therefore, the criteria for an original formal-result report of a Phase III randomised trial with a drug-containing intervention are not met. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| 99mTcPSMA-radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE-II trial. PMID 38346924 · BJU Int · 2024-Jul The record describes a trial protocol for a randomized oncology study with a time-to-event primary endpoint. However, it is not a formal result report (e.g., primary, interim, final, updated, long-term). Furthermore, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III, and the drug intervention criterion is ambiguous as the primary comparison involves a surgical procedure with ADT (a drug), but the study's core novelty is the surgical component. Therefore, eligibility cannot be established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of PD-1/PD-L1 Inhibitor and Chemotherapy in Treatment of Advanced Small Cell Lung Cancer. PMID 37971453 · Altern Ther Health Med · 2024-Jul The study is an oncology randomized controlled trial with drug intervention and original results, but it fails two key criteria: (1) the phase is not specified as Phase III/IIIb or Phase II/III (metadata and abstract do not confirm a definitive phase), and (2) a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) with time-to-event data (Kaplan-Meier, HR) is not explicitly reported; 'median survival time' is mentioned but without specification of the endpoint type or supporting time-to-event analysis. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Development and validation of nomogram for predicting early recurrence after radical gastrectomy of gastric cancer. PMID 38243254 · World J Surg Oncol · 2024-Jan-19 Study is a retrospective cohort analysis developing a predictive nomogram for early recurrence after surgery. It is not a randomized trial, does not test a drug intervention, and does not report time-to-event efficacy endpoints like OS/PFS/DFS with Kaplan-Meier or HR. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. PMID 38229199 · Trials · 2024-Jan-16 The record describes the methodology and design of a Phase 3 randomized trial with a time-to-event primary endpoint (PFS) in an oncology setting, but it is a protocol/registration abstract and does not present any formal results from the trial. Therefore, it is not an original result report and does not meet the inclusion criteria for the cohort. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904). PMID 37801434 · Jpn J Clin Oncol · 2024-Jan-07 The record describes a Phase III randomized trial with a time-to-event endpoint in oncology, but the abstract is a protocol summary without reported results, and the drug intervention is not explicitly detailed (only 'chemoradiotherapy' is mentioned without specifying agents). |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial. PMID 38167339 · Trials · 2024-Jan-02 This is a Phase III randomized trial protocol for hypofractionated radiotherapy in breast cancer. It lacks formal results (abstract describes methods, not outcomes). The intervention is non-drug (radiotherapy), and the primary efficacy endpoint is not a standard time-to-event endpoint (OS, PFS, etc.) with reported Kaplan-Meier or HR data. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. PMID 37883739 · J Clin Oncol · 2024-Jan-01 The record describes a randomized trial with drug interventions and time-to-event endpoints (PFS, OS) in oncology. However, the provided metadata (title, abstract, publication types) does not explicitly state the trial phase (Phase III, II/III, etc.). Without explicit phase information, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials. PMID 38140879 · Cancer Med · 2024-Jan The record describes a pooled analysis of individual patient data from four Japanese Phase III trials in advanced gastric cancer. While it involves oncology, humans, Phase III trials, time-to-event endpoints, and drug interventions, it is not an original result report of a single randomized trial. Instead, it is a secondary analysis investigating correlations between endpoints. Therefore, it does not meet the inclusion criteria for a primary result report of an individual randomized trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial. PMID 38049557 · Br J Cancer · 2024-Jan The record is for a published erratum correcting a prior trial report, not the original result report itself. The abstract is empty, and no time-to-event efficacy signal is present in the provided metadata. Therefore, the original result report cannot be confirmed from this record. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Outcomes of a Dietary Intervention to Reduce Bladder Cancer Recurrence and Progression in Survivors of Non-Muscle-Invasive Bladder Cancer. PMID 38408431 · J Natl Compr Canc Netw · 2024-Feb-26 Study is a randomized trial in oncology (bladder cancer) with original results, but it is not a Phase III/IIIb or Phase II/III trial (phase not specified but methods imply a pilot/intervention-focused study), does not involve a drug-containing intervention (dietary cruciferous vegetables vs general fruit/vegetable), and lacks a time-to-event efficacy endpoint (primary outcome is urinary ITC level; no OS/PFS/DFS/KM/HR reported). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Recurrences of advanced sessile and lateral spreading colorectal adenoma after endoscopic mucosal resection (EMR) thermal ablation versus no adjuvant therapy (RESPECT): a protocol of an international randomized controlled trial. PMID 38368409 · Trials · 2024-Feb-17 The record describes a protocol for an international randomized controlled trial evaluating endoscopic mucosal resection with thermal ablation for colorectal adenoma. While it is oncology, human, and randomized, it is ineligible because it is a protocol without results, the intervention is a non-drug procedural technique, and the primary endpoint is not a time-to-event efficacy measure. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer? PMID 38340705 · Med · 2024-Feb-09 The record is an editorial/commentary discussing the implications of a published trial (LIBRETTO-431) and does not present original trial results. It does not explicitly report a drug-containing intervention or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) from a randomized Phase II/III or Phase III/IIIb trial. The deterministic review correctly identified no time-to-event signal and no drug intervention signal from this text. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Erratum: Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. PMID 38113437 · J Clin Oncol · 2024-Feb-01 The record is an erratum for a Phase III trial but does not contain original result data or time-to-event efficacy endpoint information (OS, PFS, HR, KM) required for inclusion. The abstract is empty, and the publication type ('Published Erratum') indicates it is not a primary or final result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. PMID 37963317 · J Clin Oncol · 2024-Feb-01 The study is a randomized Phase II/III oncology trial with a drug intervention, but the abstract does not report any time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR data. The primary results are pathologic/surgical outcomes and safety. Therefore, it does not meet the time-to-event endpoint criterion for inclusion. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. PMID 37931185 · J Clin Oncol · 2024-Feb-01 The record reports overall survival (secondary endpoint) from the STIC CTC trial, a randomized trial in advanced breast cancer comparing CTC-count-driven therapy (endocrine therapy or chemotherapy) versus investigator choice. The trial is described as randomized and includes drug interventions. While the specific phase is not explicitly stated in the provided metadata, the trial design and reporting (comparing two active treatment strategies in advanced cancer) are consistent with a definitive Phase III trial. The result is an original report of a planned secondary endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202. PMID 38157649 · Eur J Surg Oncol · 2024-Feb The report is an exploratory subset analysis from JCOG1202 (a phase III trial) examining feasibility and toxicity after major hepatectomy, not the primary efficacy results. It lacks any reported time-to-event efficacy endpoints (OS, PFS, DFS, etc.) for the overall trial population, which is required for inclusion. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232. PMID 38062123 · Leukemia · 2024-Feb The study is from a randomized trial with drug interventions and time-to-event endpoints, but the abstract presents results primarily from a secondary analysis (osteonecrosis incidence and its association with survival) rather than the primary trial efficacy results. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the metadata. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients. PMID 37935995 · Eur J Nucl Med Mol Imaging · 2024-Feb This is a prospective single-arm observational cohort study evaluating the prognostic impact of PSMA PET/CT upstaging on biochemical recurrence-free survival in prostate cancer. It is not a randomized controlled trial, lacks a drug-containing intervention, and is not a Phase III/IIIb or Phase II/III trial report. The study mentions Phase III evidence in the literature but does not present a new Phase III trial. Therefore, it does not meet the core eligibility criteria for inclusion. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. PMID 37923838 · Nat Med · 2024-Feb The record is a 'Publisher Correction' (erratum) for the CheckMate 76K trial. While the title references a 'phase 3' trial with 'primary results', the empty abstract and erratum publication type prevent reliable verification of the human subject, time-to-event endpoint, and original result criteria. Metadata is insufficient to establish eligibility. |
H
|
仅历史库存 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study. PMID 37581654 · Eur Radiol · 2024-Feb The study is a randomized trial in human oncology (HCC) with a primary time-to-event endpoint (PFS) and a secondary time-to-event endpoint (OS), comparing a drug intervention (CalliSpheres beads loaded with arsenic trioxide) to a control (conventional TACE), and reports formal comparative results. However, the phase (III/IIIb or II/III) is not explicitly established in the provided record, preventing full eligibility confirmation. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The Mucosal Protection in the Treatment of Erosive Reflux Esophagitis: Mechanisms for Restoring Epithelial Permeability. A Randomized Clinical Trial. PMID 39733305 · J Gastrointestin Liver Dis · 2024-Dec-28 The study is a randomized trial of drug intervention for erosive gastroesophageal reflux disease (GERD), not a human malignant neoplasm. It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| PTSD Coach as an early mobile intervention to improve cancer-related anxiety and psychosocial oncology uptake in patients newly diagnosed with head and neck cancer: pilot randomized controlled trial. PMID 39709459 · Pilot Feasibility Stud · 2024-Dec-21 This is a pilot randomized controlled trial of a psychosocial mobile app intervention (PTSD Coach) for head and neck cancer patients. It does not involve a drug intervention, does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.), and is a feasibility/pilot study rather than a definitive Phase III trial with efficacy results. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual Trial. PMID 39002849 · Int J Radiat Oncol Biol Phys · 2024-Dec-01 The record describes the initial results from a non-randomized phase I safety cohort of a phase III trial. It does not contain a drug intervention or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The report type is best classified as 'other' as it is an initial report from a trial component, not the primary analysis of the randomized phase. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A commentary on 'Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial'. PMID 38814288 · Int J Surg · 2024-Dec-01 This is a commentary on a phase III trial, not the original trial report itself. It lacks an abstract and does not explicitly report time-to-event efficacy results (e.g., OS, PFS, KM curves, HR) from the original trial. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials. PMID 39322715 · Leukemia · 2024-Dec While the record describes a comparison of two phase 3 randomized oncology trials, the title and provided metadata lack any signal of a time-to-event efficacy endpoint (KM curves, HR, or specific survival outcomes). It is also a retrospective comparative study, not an original result report of a single trial. Therefore, it does not meet all eligibility criteria. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of hepatic arterial infusion chemotherapy combined with donafenib in the treatment of unresectable hepatocellular carcinoma. PMID 39183450 · Asia Pac J Clin Oncol · 2024-Dec Phase information is not explicitly stated in the provided metadata. The record is labeled as a Randomized Controlled Trial, and the title/abstract describe a clinical study, but the trial phase (Phase II/III or Phase III/IIIb) is not mentioned. Therefore, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| An Integrated Approach Using Network Pharmacology and Experimental Validation to Reveal the Therapeutic Mechanism of Weifuchun in Treating Gastric Cancer. PMID 39142714 · J Med Food · 2024-Dec The study is an oncology RCT with a drug intervention and original results, but it does not meet all required criteria for eligibility: the phase is not specified as Phase III/IIIb or II/III (cannot be inferred), and the primary endpoint is recurrence and metastasis rates, not a time-to-event endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR analysis. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL. PMID 38518104 · Blood · 2024-Aug-29 While the publication types indicate a Phase III randomized trial in human oncology with drug intervention and original results, the abstract does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier survival analysis or hazard ratio for efficacy. The survival analysis mentioned relates to genomic complexity as a prognostic factor, not a drug intervention's efficacy. Therefore, it fails the time-to-event efficacy endpoint criterion. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A seamless phase II/III design with dose optimization for oncology drug development. PMID 38845095 · Stat Med · 2024-Aug-15 The record describes a proposed trial design (protocol) without presenting original results from a randomized controlled trial. It lacks a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation. PMID 39134959 · BMC Cancer · 2024-Aug-13 Study is a randomized, oncology trial in human lymphoma patients comparing two drug-containing conditioning regimens with reported OS and PFS results. However, the explicit trial phase (e.g., Phase III) is not confirmed in the provided title, abstract, or metadata, preventing definitive eligibility determination. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. PMID 38833659 · J Clin Oncol · 2024-Aug-10 The study is a randomized Phase III oncology trial with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, EFS, RFS, TTP) or related analyses (Kaplan-Meier, HR). The primary endpoint (complete response rate) and secondary endpoint (proportion free of nausea) are categorical proportions, not time-to-event outcomes. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. PMID 38701390 · J Clin Oncol · 2024-Aug-10 The record describes an ancillary/prognostic analysis (MRD status) from a randomized trial (STaMINA). While it meets criteria for oncology, human, randomized, time-to-event, and drug intervention, the explicit Phase III designation is not confirmed in the metadata. Furthermore, the report type is a secondary/prognostic analysis of the trial, not the primary result report of the randomized treatment comparison. Therefore, eligibility cannot be fully established; phase is uncertain, and it is not a primary result report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Barriers and proposed solutions to at-home colorectal cancer screening tests in medically underserved health centers across three US regions to inform a randomized trial. PMID 39118261 · Cancer Med · 2024-Aug Qualitative study to inform the design of a future pragmatic trial; does not report results of a randomized drug intervention trial with time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Increasing Uptake of Lung Cancer Screening Among Emergency Department Patients: A Pilot Study. PMID 38839453 · J Emerg Med · 2024-Aug The study is an oncology, human, randomized, original-result trial, but it is a pilot/feasibility study (not Phase III), does not involve a drug-containing intervention (text message and referral are non-drug), and does not report a time-to-event efficacy endpoint (OS, PFS, etc.). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy. PMID 38592710 · Blood Adv · 2024-Apr-09 Eligible for inclusion as human oncology RCT with drug intervention and time-to-event endpoint, but excluded because it is a Phase II/feasibility trial (not Phase III/IIIb) and the primary efficacy endpoint is not a formal time-to-event efficacy endpoint (OS/PFS/DFS etc.) as required. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials. PMID 38593674 · Gynecol Oncol · 2024-Apr The report is an original secondary analysis of racial disparities in outcomes across multiple data sources, including pooled trial data. While it includes randomized phase III trial data with time-to-event endpoints, it does not present the primary or key secondary efficacy results of a single drug-containing intervention trial. The drug intervention is not explicitly detailed for the trials included in the pooled analysis, making it impossible to confirm a drug-containing intervention as required. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| MIRO study: Do the results of a randomized controlled trial apply in a real population? PMID 38490752 · Surgery · 2024-Apr The record is a secondary analysis of a prior RCT, not an original trial report. It is a non-randomized cohort study focusing on surgical approaches for a postoperative complication endpoint, lacking a drug intervention and time-to-event efficacy outcomes (OS, PFS, etc.). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. PMID 38467131 · Lancet Oncol · 2024-Apr The study is an oncology, human, phase 3b trial with a drug intervention and reports original results. However, it is a single-arm (non-randomized) trial, and its primary activity endpoint is complete remission rate, a categorical response endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier survival analysis, or hazard ratio). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Intraoperative Music to Promote Patient Outcome (IMPROMPTU): A Double-Blind Randomized Controlled Trial. PMID 38306934 · J Surg Res · 2024-Apr The study is a randomized, double-blind trial in oncology patients, but it does not involve a drug-containing intervention (the intervention is intraoperative music). Furthermore, the primary endpoint is postoperative pain (a patient-reported outcome), and secondary endpoints include complications, length of stay, and mortality, but no time-to-event efficacy endpoints (e.g., OS, PFS, DFS, HR, Kaplan-Meier analysis) are reported. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Intraoral appliance treatment modulates inflammatory markers and oxidative damage in elderly with sleep apnea. PMID 39661789 · Braz Oral Res · 2024 The study is a randomized trial but does not meet the required oncology domain. It investigates obstructive sleep apnea (non-malignant), uses a device intervention (intraoral appliance, not a drug), and reports biomarker/clinical outcome endpoints (AHI, ODI, inflammatory markers) rather than a time-to-event efficacy endpoint such as OS, PFS, or DFS. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The intervention effect of psychological care combined with ondansetron, dexamethasone, and promethazine hydrochloride on chemotherapy in breast cancer surgical patients. PMID 39520157 · Technol Health Care · 2024 Eligibility requires a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) in a Phase III/IIIb or Phase II/III randomized trial. This study is randomized and includes a drug intervention, but it lacks any time-to-event endpoint and does not specify a Phase III/IIIb or Phase II/III design. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Comparing Participation and Interim Effectiveness of Endoscopy and Biomarker-Based Screening for Gastric Cancer: A Cluster Randomized Controlled Trial. PMID 39440067 · J Cancer · 2024 The record describes a randomized trial comparing screening methods for gastric cancer, but it lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The phase is not explicitly confirmed as Phase III/IIIb or II/III. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials. PMID 39315334 · Front Cell Infect Microbiol · 2024 The study is an oncology, human, randomized, Phase III trial with a drug (vaccine) intervention and an original result. However, it is excluded because the primary efficacy endpoint is not a time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The endpoint is vaccine efficacy against CIN3/AIS, measured as a percentage reduction in case counts over a fixed follow-up period, not a time-to-event outcome. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations. PMID 39229786 · Future Oncol · 2024 The record is a protocol for an ongoing randomized Phase III trial. It is not an original result report with efficacy data, which is required for inclusion in the KM digitization cohort. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO). PMID 39193150 · Front Neurol · 2024 The record is a Phase 3, randomized, drug-intervention trial protocol for autoimmune encephalitis, which is a non-oncology condition. It does not report results, and the primary efficacy endpoint is a binary outcome at Week 24, not a time-to-event endpoint (OS, PFS, etc.). Therefore, it is ineligible. |
H
|
仅历史库存 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Assessing Fidelity in Yoga Interventions for Chemotherapy-Induced Peripheral Neuropathy: Decision-Making to Enhance Protocol Quality Adherence. PMID 39066651 · Integr Cancer Ther · 2024 The record is a methodological article about fidelity monitoring for an ongoing trial. It does not contain the formal, primary results of the trial's efficacy analysis with a time-to-event endpoint. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |